Powering the Immune System to Transform Lives

Our Pipeline

A Deep, Broad Pipeline to Address Unmet Patient Need

Our deep and broad pipeline contains multiple clinical-stage and preclinical candidates for diseases with significant unmet patient need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world. 

Hepatitis Delta

tobevibart1 + elebsiran2,3

Goal:
Treatment
Phase:
Phase 3,75%

Learn more about our therapeutic focus on Hepatitis Delta

Solid Tumors

VIR-5818 (HER2)4 ± pembrolizumab

Goal:
Treatment
Phase:
Phase 1,75%

VIR-5500 (PSMA)4,5 ± ARPIs

Goal:
Treatment
Phase:
Phase 1,75%

VIR-5525 (EGFR)4 ± pembrolizumab

Goal:
Treatment
Phase:
Phase 1,75%

Undisclosed PRO-XTEN® TCE targets6

Goal:
Treatment
Phase:
Pre-clinical,75%

Learn more about our therapeutic focus on Oncology

HIV Cure

Preclinical antibody candidates

Collaborator:
Gates Foundation
Goal:
Treatment
Phase:
Pre-clinical,75%

Learn more about our therapeutic focus on HIV

1 Tobevibart incorporates Xencor’s Xtend™ and other Fc technologies
2 Norgine holds exclusive license for the commercial rights to the combination of tobevibart and elebsiran in Europe, Australia and New Zealand
3 Brii Biosciences retains rights to the combination of tobevibart and elebsiran in the Greater China Territory (People’s Republic of China, Hong Kong, Taiwan and Macau)
4 Masked TCEs licensed from Sanofi
5 Upon closing of the Astellas global collaboration, which is contingent on customary closing conditions, including clearance under the Hart-Scott-Rodino (HSR) Act, Astellas will hold co-development and co-commercialization rights for VIR-5500 for the treatment of prostate cancer
6 Vir Biotechnology has exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company

HER2: human epidermal growth factor receptor 2; PSMA: prostate-specific membrane antigen; ARPIs: androgen receptor pathway inhibitors; EGFR: epidermal growth factor receptor; TCE: T-cell engager; HIV: human immunodeficiency virus